Press Releases
June 1, 2004
Xanodyne Completes $20 million Series C Financing
FOR IMMEDIATE RELEASE
FLORENCE, KY – June 1, 2004 – Xanodyne Pharmaceuticals, Inc., the privately owned specialty pharmaceutical company based in Florence, KY announced the completion of its Series C Financing to raise $20 million. The financing was underwritten by Xanodyne’s three principle venture capital backers, Blue Chip Venture Company, Essex Woodlands Health Ventures and HealthCare Ventures with additional existing investors having an opportunity to invest on a pro rata basis.
Xanodyne is focused on women’s health, urology and pain management. The proceeds of the financing will be used to expand its national field sales team and fund its development programs for Misopess (for cervical ripening) and XP012B (for menorrhagia), both of which will enter Phase III later this year.
Additional information may be found on the Xanodyne web site at www.xanodyne.com.
###